New Nasal Spray Formulation
One of the most common problems associated with chronic rhinosinusitis is that there is no effective treatment. A combination of budesonide and povidone-iodine nasal aerosol is now being developed. This combination is a breakthrough in rhinology, and represents a new standard for resolving these issues. It is also safe for children to use and can be used to treat a variety of allergic reactions and respiratory conditions.
A new study by the University of Kentucky is exploring a new antiseptic nasal spray formulation containing povidone-iodine. The researchers are assessing the safety and effectiveness of this agent in treating COVID-19 and other viral infections. This new antiviral formulation is an antiviral treatment that reduces the viral load in patients with mild to moderate symptoms. Until now, only a few trials have been conducted on this agent.
While 1% iodine nasal spray protocol is not a cure-all, it can reduce the risk of SARS. In vitro tests have shown that PI can completely inactivate the SARS-CoV-2 virus within 15 seconds. In humans, a 0.5% concentration of PI has cytotoxic effects on the SARS-CoV-2 virus but does not cause a toxicity.
New Nasal Spray Formulation With Budesonide and Povidone-Iodine
The safety profile of povidone-iodine nasal antiseptics is a major consideration when choosing a product to treat a cold or flu. Research has shown that the solution can kill SARS-CoV-2 in 15 seconds. Its 1.25% concentration has also been shown to be safe for intranasal administration and to play an adjunctive role in reducing viral transmission.
Clinical studies have shown that povidone-iodine is safe for use in the nasal cavity and oral cavity. Its effectiveness against SARS-CoV-2 has also been demonstrated in laboratory studies. This topical formulation has been used for more than 5 years and has been recommended for this purpose. In vitro testing shows that the solution is effective in inactivating SARS-CoV-2.
In addition to being effective, povidone-iodine nasal antiseptic solutions have also proven effective in reducing the viral load in the upper aerodigestive tract. The 0.25-molar concentration of PI inhaled by a patient has been shown to reduce SARS-CoV-2 by 99% in vitro. When applied in the nasal cavity, the solution can effectively reduce the viral load.
The PVP-1 nasal spray formulation, which is a combination of iodine and polyvinyl pyrrolidone, has been used for decades to fight the spread of the SARS-CoV infection. In fact, the new formulation can successfully inactivate the virus in a matter of minutes, according to the study published in BioRxiv. Compared to placebo, the PVP-1 nasal spray is more effective than the placebo in preventing SARS.